Information for patients
We are moving from promise to practice in the clinic.View our clinical trials
ASG-22ME is an antibody-drug conjugate (ADC) targeting Nectin-4, which can be found on multiple cancers, including bladder, breast, lung and pancreatic. The antibody is attached to a potent, synthetic cytotoxic (cell-killing) agent, monomethyl auristatin E (MMAE), via an enzyme-cleavable linker using Seattle Genetics' proprietary technology.
The linker system is designed to be stable in the bloodstream and release the cell-killing agent once inside target cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects patients may experience during treatment with traditional chemotherapy while enhancing the antitumor activity.
We are co-developing ASG-22ME under an agreement with Agensys, an affiliate of Astellas. ASG-22ME is in a phase 1 clinical trial to evaluate the safety and antitumor activity of escalating doses of ASG-22ME in patients with solid tumors.